Communicators

Martinsried/ Munich (30.10.2019) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Medigene's management and/or scientists will be available for one-on-one meetings at these events.

SITC (Society for Immunotherapy of Cancer) 34th Annual Meeting

Date: 6 - 10 November 2019

Location: National Harbor, USA

BIO Europe

Date: 11 - 13 November 2019

Location: Hamburg, Germany

Jefferies London Healthcare Conference

Date: 20 - 21 November 2019

Location: London, UK

Cell Therapy Manufacturing & Gene Therapy Congress

Date: 3 - 6 December 2019

Location: Amsterdam, Netherlands

61st ASH Annual Meeting & Exposition

Date: 7 - 10 December 2019

Location: Orlando, USA

ESMO Immuno-Oncology Congress 2019

Date: 11 - 14 December 2019

Location: Geneva, Switzerland

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG

Dr Gary Waanders,

Claudia Burmester, Dr Anna Niedl

Tel.: +49 - 89 - 20 00 33 - 33 01,

email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg

country: Germany

contact person: Medigene PR/IR

phone: +49 - 89 - 20 00 33 - 33 01

e-mail: investor@medigene.com

website: www.medigene.de

ISIN(s): DE000A1X3W00 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate